Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 2, 2009, Pages 379-382

  Nagasaki, Yoji ^a   Eriguchi, Yoshihiro ^a   Uchida, Yujiro ^b   Miyake, Noriko ^a   Maehara, Yoriko ^a   Kadowaki, Masako ^a   Harada, Mine ^a,c   Akashi, Koichi ^a   Shimono, Nobuyuki ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY HOSPITAL   (Japan)

^c Omuta National Hospital   (Japan)

Author keywords

Fungal burden; Galactmannan index; Histopathology; Primary therapy

Indexed keywords

AMPHOTERICIN B; CYCLOPHOSPHAMIDE; GALACTOMANNAN; MICAFUNGIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HISTOPATHOLOGY; IMMUNE DEFICIENCY; KIDNEY; LUNG ASPERGILLOSIS; LUNG PARENCHYMA; MOUSE; NONHUMAN; SPLEEN; SURVIVAL;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FEMALE; IMMUNOCOMPROMISED HOST; INVASIVE PULMONARY ASPERGILLOSIS; KIDNEY; LIPOPEPTIDES; LUNG; MANNANS; MICE; MICE, INBRED ICR; SPLEEN; SURVIVAL ANALYSIS;

EID: 67650739469     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp175     Document Type: Article

References (10)

1. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32 358-66.
2. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-51.
3. Branch RA. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med 1988; 148: 2389-94.
4. Philip A, Odabasi Z, Rodriguez J et al. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother 2005; 49: 3572-4.
5. Maertens J, Glasmacher A. Multicenter, noncomparative study of caspofingin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006; 15: 2888-97.
6. Sionov E, Mendlovic S, Segal E. Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis. J Infect 2006; 53: 131-9.
7. Graybill JR, Bocanegra R, Gonzalez GM et al. Combination anti-fungal therapy of murine aspergillosis: Liposomal amphotericin B and micafungin. J Antimicrob Chemother 2003; 52: 656-62.
8. Boutboul F, Alberti C, Leblanc T et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: Increasing antigenemia is associated with progressive disease. Clin Infect Dis 2002; 34 939-43.
9. Petraitis V, Petraitiene R, Groll AH et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002; 46: 1857-69.
10. Mukherjee PK, Sheehan DJ, Hitchcock CA et al. Combination treatment of invasive fungal infections. Clin Microbiol Rev 2005; 18: 163-94.